Artivila Therapeutics
Shenzhen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $42M
Overview
Clinical-stage biotech using AI-powered drug discovery to develop first-in-class therapies for autoimmune diseases, neurodegenerative disorders, and cancers.
OncologyImmunology
Technology Platform
Proprietary integrated platform combining Artificial Intelligence-Driven Drug Discovery (AIDD) and Computer-Aided Drug Design (CADD) for accelerated identification and optimization of novel drug candidates.
Opportunities
Significant opportunity to validate AI-driven drug discovery platform through clinical success of ARD-885, potentially enabling expansion into additional autoimmune and oncology indications.
Growing demand for innovative therapies in China's pharmaceutical market.
Risk Factors
Clinical development risks for lead asset ARD-885, competition from established pharmaceutical companies and other AI-driven biotechs, and dependence on continued funding to advance pipeline programs.
Competitive Landscape
Competes with traditional pharma companies and other AI-driven biotechs like Exscientia, Recursion, and Insilico Medicine; differentiation comes from integrated AIDD/CADD platform and focus on first-in-class therapies for autoimmune and neurodegenerative diseases.